Date:12/11/2009

ributable to ordinary shares -Basic 0.04 0.29 (0.01) 0.02 0.12 (0.43) -Diluted 0.04 0.27 (0.01) 0.02 0.11 (0.43) Attributable to redeemable ordinary shares -Basic N/A N/A 0.42 0.13 0.92 0.44 -Diluted N/A N/A 0.42 0.13 0.92 0.44 Exhibit 3 CHINA CORD BLOOD CORPORATION Reconciliations of non-GAAP results of operations measures to the nearest comparable GAAP measures Three Three Three Six Six Six months months months months months months Ended Ended Ended Ended Ended Ended Sep 30, Sep 30, Sep 30, Sep 30, Sep 30, Sep 30, 2009 2009 2008 2009 2009 2008 US$ RMB RMB US$ RMB RMB ('000) ('000) ('000) ('000) ('000) ('000) GAAP Operating Income 3,537 24,144 24,832 6,914 47,199 33,735 Depreciation 664 4,537 1,473 1,323 9,027 2,868 Amortization 36 243 243 71 485 485 Earnings before interest, tax, depreciation and amortization ("Non -GAAP EBITDA") 4,237 28,924 26,548 8,308 56,711 37,088 Exhibit 4 CHINA CORD BLOOD CORPORATION Reconciliations of non-GAAP EPS to the nearest comparable GAAP measures 3 Months 3 Months 6 Months 6 Months Ended Sep 09 Ended Sep 08 Ended Sep 09 Ended Sep 08 NUMERATOR ('RMB '000) GAAP net income/ (loss) attributable to China Cord Blood Corporation Shareholders 17,639 5,779 1
'/>"/>

SOURCE China Cord Blood Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Related medicine news :

1. China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009
2. Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China
3. ESC to give talks on diabetes in 3 cities in China
4. China Medical Technologies Reports Second Fiscal Quarter Financial Results
5. China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009
6. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
7. Novartis to Acquire Majority Stake in Hard to Treat Diseases (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million
8. Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin
9. HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China
10. China Nepstar Enters Into Strategic Cooperation Agreement with ATMU to Install More Than 1,000 ATMs in Nepstar Stores
11. China Medical Technologies to Announce Unaudited Financial Results for the Second Fiscal Quarter Ended September 30, 2009 on November 19, 2009